TITUSVILLE, N.J., March 5, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administratio
Source: www.prnewswire.com
Janssen Pharmaceutical Companies of Johnson & Johnson has received U.S. Food and Drug Administration (US FDA) approval for SPRAVATO (esketamine) CIII nasal spray. This drug can be used in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD). It is estimated that approximately one-third of U.S. adults with MDD have TRD.
